The
Latest
The Latest
News
Numinus Announces Grant of Stock Options
News
EGF Theramed Raises $352,502 in First Tranche of Private Placement
News
Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder
News
Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units
More Articles
FEATURED
Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics
News
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
News
Mount Sinai Health System Launches Center for Psychedelic Research
Trending
#
News
Field Trip Health Ltd. Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin Services
#
News
Tryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific Officer
#
News
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth
#
Spotlight
Matthew Johnson
#
Spotlight
Garyn Angel | Founder & CEO, Magical Brands
Companies
#
Tryp Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
#
Diamond Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
#
Mind Medicine (MindMed)
NEO
NASDAQ
CSE
TSXV
Private Company
#
Havn Life
NEO
NASDAQ
CSE
TSXV
Private Company
#
Mydecine Innovations Group
NEO
NASDAQ
CSE
TSXV
Private Company
Features
News
Numinus Announces Grant of Stock Options
News
EGF Theramed Raises $352,502 in First Tranche of Private Placement
News
Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder
News
Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units
© year Psychedelic Finance